RAD — Radiopharm Theranostics Share News
0.000.00%
Last trade - 00:00- AU$70.88m
- AU$34.53m
- AU$3.63m
NASDAQ RESUMED AT 02:11 PM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 02:06 PM
Brief: Radiopharm Theranostics Announces 50% Enrollment In Phase 2B Clinical Trial Of Rad101 Imaging In Brain Metastases
Australia's Radiopharm Theranostics slumps on discounted placement
Brief: Radiopharm Theranostics Completes A$35 M Placement
Brief: Radiopharm Theranostics Ltd Seeks Trading Halt
Brief: Radiopharm Gets DSMC Nod To Accelerate Phase 1 Dose Escalation Trial Of 177Lu-RAD202
Brief: Radiopharm Theranostics Ltd Co Partners With Starpharma On Research And Option Agreement To Develop Novel Radiotherapy Asset
Australia's Starpharma jumps on plans to develop novel radiotherapy treatment
Brief: Starpharma Holdings Signs Research And Option Agreement With Radiopharm Theranostics
Brief: Radiopharm Theranostics Reports FY Loss Attributable A$36.7 Million
Brief: Radiopharm Theranostics Confirmed Guidance Of Cash Runway Through To Mid-2026
Brief: Radiopharm Theranostics To Start Rv-01 Study In 4Q25
Brief: Radiopharm Theranostics Receives IND Approval From US FDA For Betabart (Rv-01)
Brief: Radiopharm Theranostics and Cyclotek Sign Clinical Supply Agreement for ¹⁶¹Tb-KLK3-mAb Phase I Clinical Trial in Australia
Brief: Radiopharm Theranostics Signs Supply Agreement With Cyclotek
Australia's Radiopharm Theranostics jumps on FDA's Fast Track Designation for product
Brief: Radiopharm Theranostics Says Rad Granted Us FDA Fast Track For Rad101 Metastases Imaging
Brief: Radiopharm Theranostics Says ITM Isotope Technologies Munich SE And Co Sign Supply Agreement